Who are Auris-Sedina's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sevoflurane + Remifentanyl, Sevoflurane intravenous anesthesia, SAGE-547, Remifentanil and/or propofol, The midazolam ketamine group, intravenous sedation with propofol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/auris-sedina.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Auris-Sedina — Competitive Intelligence Brief

Auris-Sedina (Auris-Sedina) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Benzodiazepine. Area: Neurology.

phase 3 Benzodiazepine GABA_A receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Auris-Sedina (Auris-Sedina) — Laboratorios Osorio de Moraes Ltda.. Auris-Sedina is a sedative-hypnotic agent used to treat insomnia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Auris-Sedina TARGET	Auris-Sedina	Laboratorios Osorio de Moraes Ltda.	phase 3	Benzodiazepine	GABA_A receptor
Sevoflurane + Remifentanyl	Sevoflurane + Remifentanyl	Azienda Ospedaliera San Gerardo di Monza	phase 3	General anesthetic and opioid analgesic	GABA_A receptor and opioid receptors
Sevoflurane intravenous anesthesia	Sevoflurane intravenous anesthesia	The Cleveland Clinic	phase 3	Volatile anesthetic	GABA_A receptor
SAGE-547	SAGE-547	Supernus Pharmaceuticals, Inc.	phase 3	antisense oligonucleotide	GABA_A receptor alpha 1 subunit
Remifentanil and/or propofol	Remifentanil and/or propofol	Alder Hey Children's NHS Foundation Trust	phase 3	Opioid analgesic, Sedative-hypnotic	Opioid receptors, GABA_A receptor
The midazolam ketamine group	The midazolam ketamine group	Kasr El Aini Hospital	phase 3	Benzodiazepine and NMDA receptor antagonist	GABA_A receptor, NMDA receptor
intravenous sedation with propofol	intravenous sedation with propofol	University Hospital, Clermont-Ferrand	phase 3	GABA_A receptor agonist	GABA_A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Benzodiazepine class)

Hamad Medical Corporation · 3 drugs in this class
Lundbeck LLC · 2 drugs in this class
UCB Biopharma SRL · 2 drugs in this class
Universitaire Ziekenhuizen KU Leuven · 2 drugs in this class
Bausch Health · 1 drug in this class
Centro Medico Nacional La Raza, IMSS · 1 drug in this class
Assaf-Harofeh Medical Center · 1 drug in this class
Daegu Catholic University Medical Center · 1 drug in this class
B.P. Koirala Institute of Health Sciences · 1 drug in this class
Consorci Sanitari de l'Anoia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Auris-Sedina — Competitive Intelligence Brief. https://druglandscape.com/ci/auris-sedina. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab